Seminars in Hematology
Volume 43 , Pages S23-S27 , April 2006

Consideration in Hemophilia Therapy Selection

  • Steven Pipe

      Affiliations

    • Corresponding Author InformationAddress correspondence to Steven Pipe, MD, Pediatric Medical Director, Hemophilia and Coagulation Disorders Program, University of Michigan, Room L2110 Women’s Hospital, 1500 E Medical Center Dr, Ann Arbor, MI 48109.

References 

  1. Hilgartner MW . The need for recombinant factor VIII (Historical background and rationale) . Semin Hematol . 1991;28(suppl 1):6–9
  2. Centers for Disease Control and Prevention . Report on the Universal Data Collection Program, 6 (No. 2) . 2004; Available at http://www.cdc.gov/ncbddd/hbd/documents/UDC6(2).pdf, accessed November 2005
  3. Mauser-Bunschoten EP , Roosendaal G , van den Berg HM . Product choice and haemophilia treatment in the Netherlands . Haemophilia . 2001;7:96–98
  4. Mantovani LG , Monzini MS , Mannucci PM , Scalone L , Villa M , Gringeri A . Differences between patients’, physicians’ and pharmacists’ preferences for treatment products in haemophilia (A discrete choice experiment) . Haemophilia . 2005;11:589–597
  5. Brown SA , Aledort LM , Lee CA . Issues in making a therapeutic choice (Recombinant and/or human-derived products) . Haemophilia . 2000;6:125–129
  6. Aledort LM . Making a therapeutic choice (Human versus recombinant fractions—Can we do it?) . Haemophilia . 2001;7(suppl 1):1–3
  7. Farrugia A . Evolving perspectives in product safety for haemophilia . Haemophilia . 2002;8:236–243
  8. Miller R . The responsibility of separating truth from myth to patient and family . Haemophilia . 2001;7:91–95
  9. Magli-Barioz D , Ounnoughene N , Paugy P , Quarre MC , Vassilief D , Lopez I , et al.   Evaluation of the impact of information about treatment-related risks in patients receiving blood-derived or recombinant medications . Haemophilia . 2004;10:572–581
  10. Giangrande PL . Treatment of hemophilia: Recombinant factors only? Yes . J Thromb Haemost . 2003;1:214–215
  11. Kasper CK . Concentrate safety and efficacy . Haemophilia . 2002;8:161–165
  12. AABB: All About Blood. Available at: http://www.aabb.org/All_About_Blood/FAQs/aabb_faqs.htm, accessed December 2005
  13. Giachetti C , Linnen JM , Kolk DP , Dockter J , Gillotte-Taylor K , Park M , et al.   Highly sensitive multiplex assay for detection of human immunodeficiency virus type 1 and hepatitis C virus RNA . J Clin Microbiol . 2002;40:2408–2419
  14. Food and Drug Administration . Guidance for Industry (Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of HIV-1 and HCV) . Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2004;
  15. Centers for Disease Control and Prevention . Update (West Nile Virus screening of blood donations and transfusion-associated transmission—United States, 2003) . MMWR Morb Mortal Wkly Rep . 2004;53:281–284
  16. Rajcani J . Molecular mechanisms of virus spread and virion components as tools of virulence. A review . Acta Microbiol Immunol Hung . 2003;50:407–431
  17. Klempner MS , Shapiro DS . Crossing the species barrier—One small step to man, one giant leap to mankind . N Engl J Med . 2004;350:1171–1172
  18. Chandran K , Farsetta DL , Nibert ML . Strategy for nonenveloped virus entry (A hydrophobic conformer of the reovirus membrane penetration protein micro 1 mediates membrane disruption) . J Virol . 2002;76:9920–9933
  19. Knight RS , Will RG . Prion diseases . J Neurol Neurosurg Psychiatry . 2004;75(suppl 1):i36–i42
  20. Jakubik JJ , Vicik SM , Tannatt MM , Kelley BD . West Nile virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes for B-domain deleted recombinant factor VIII . Haemophilia . 2004;10:69–74
  21. Goodnough LT . Risks of blood transfusion . Crit Care Med . 2003;31(suppl 12):678–686
  22. Miekka SI , Busby TF , Reid B , Pollock R , Ralston A , Drohan WN . New methods for inactivation of lipid-enveloped and non-enveloped viruses . Haemophilia . 1998;4:402–408
  23. Yokoyama T , Murai K , Murozuka T , Wakisaka A , Tanifuji M , Fujii N , et al.   Removal of small non-enveloped viruses by nanofiltration . Vox Sang . 2004;86:225–229
  24. Soucie JM , Richardson LC , Evatt BL , Linden JV , Ewenstein BM , Stein SF , et al.   Risk factors for infection with HBV and HCV in a large cohort of hemophiliac males . Transfusion . 2001;41:338–343
  25. Chambost H , Ljung R . Changing pattern of care of boys with haemophilia in western European centres . Haemophilia . 2005;11:92–99
  26. Giangrande P . Haemophilia B (Christmas disease) . Expert Opin Pharmacother . 2005;6:1517–1524
  27. Giles AR , Rivard GE , Teitel J , Walker I . Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy . Transfus Sci . 1998;19:139–148
  28. National Hemophilia Foundation . MASAC recommendations concerning the treatment of hemophilia and other bleeding disorders . 2003; MASAC Document #151, Nov. Available at: www.hemophilia.org/research/masac/masac151.pdf, accessed July 2004
  29. United Kingdom Haemophilia Centre Doctors’ Organisation . Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders . Haemophilia . 2003;9:1–23
  30. Association of Hemophilia Clinic Directors of Canada . Clinical Practice Guidelines (Hemophilia and von Willebrand’s Disease) . 1999; (2. Management; Update 2). July 7. Available at http://www.ahcdc.ca/Management.htm, accessed December 2005
  31. Abshire TC , Brackmann HH , Scharrer I , Hoots K , Gazengel C , Powell JS , et al.   Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy—International Kogenate-FS Study Group . Thromb Haemost . 2000;83:811–816
  32. Mitterer A , Mundt W , Bjornson E , Dorner F . Development of an advanced category recombinant FVIII, anti-hemophilic factor (recombinant) plasma/albumin-free method (rAHF-PFM) . J Thromb Haemost . 2003;1(suppl 1):P1652; (abstr)
  33. Lusher JM . First and second generation recombinant factor VIII concentrates in previously untreated patients (Recovery, safety, efficacy, and inhibitor development) . Semin Thromb Hemost . 2002;28:273–276
  34. Gringeri A , Tagliaferri A , Tagariello G , Morfini M , Santagostino E , Mannucci P  ReFacto-AICE Study Group . Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII . Br J Haematol . 2004;126:398–404
  35. Lusher JM . Hemophilia treatment. Factor VIII inhibitors with recombinant products: Prospective clinical trials . Haematologica . 2000;85(suppl 10):2–5
  36. Mauser-Bunschoten EP , van der Bom JG , Bongers M , Twijnstra M , Roosendaal G , Fischer K , et al.   Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A . Haemophilia . 2001;7:364–368
  37. Scharrer I , Bray GL , Neutzling O . Incidence of inhibitors in haemophilia A patients—A review of recent studies of recombinant and plasma-derived factor VIII concentrates . Haemophilia . 1999;5:145–154
  38. Mannucci PM , Schimpf K , Abe T , Aledort LM , Anderle K , Brettler DB , et al.  International Investigator Group   Low risk of viral infection after administration of vapor-heated factor VIII concentrate . Transfusion . 1992;32:134–138
  39. Ironside JW . The spectrum of safety (Variant Creutzfeldt-Jakob disease in the United Kingdom) . Semin Hematol . 2003;40:16–22
  40. Ironside JW , Head MW . Variant Creutzfeldt-Jakob disease (Risk of transmission by blood and blood products) . Haemophilia . 2004;10(suppl 4):64–69
  41. Dunstan RA , Alpers MP . Variant Creutzfeldt-Jakob disease (implications for the health care system) . Aust NZ J Public Health . 2005;29:308–312

PII: S0037-1963(06)00026-6

doi: 10.1053/j.seminhematol.2006.02.002

Seminars in Hematology
Volume 43 , Pages S23-S27 , April 2006

Article Tools